56 reports of this reaction
1.3% of all ALUMINUM HYDROXIDE reports
#18 most reported adverse reaction
PULMONARY EMBOLISM is the #18 most commonly reported adverse reaction for ALUMINUM HYDROXIDE, manufactured by Rugby Laboratories. There are 56 FDA adverse event reports linking ALUMINUM HYDROXIDE to PULMONARY EMBOLISM. This represents approximately 1.3% of all 4,296 adverse event reports for this drug.
Patients taking ALUMINUM HYDROXIDE who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for ALUMINUM HYDROXIDE, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for ALUMINUM HYDROXIDE:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 56 FDA reports for ALUMINUM HYDROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 1.3% of all adverse event reports for ALUMINUM HYDROXIDE, making it a notable side effect.
If you experience pulmonary embolism while taking ALUMINUM HYDROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.